Case Report
BibTex RIS Cite
Year 2022, Volume: 39 Issue: 3, 913 - 915, 30.08.2022

Abstract

References

  • [1] B. M. Sibai, “Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count,” Obstet. Gynecol., vol. 103, no. 5 I, pp. 981–991, 2004, doi: 10.1097/01.AOG.0000126245.35811.2a.
  • [2] H. Wulf, “[Anesthesia and intensive therapy of pregnant women with the HELLP syndrome],” Anaesthesist, vol. 39, no. 2, pp. 117–121, Feb. 1990, Accessed: Jan. 26, 2022. [Online]. Available: https://europepmc.org/article/med/2310003.
  • [3] D. Ben Letaifa et al., “[Maternal and perinatal morbidity and mortality associated with hellp syndrome] .,” Ann. Fr. Anesth. Reanim., vol. 19, no. 10, pp. 712–718, Dec. 2000, doi: 10.1016/S0750-7658(00)00313-0.
  • [4] R. K. S. Whitta, D. J. A. Cox, and S. V. Mallett, “Thrombelastography reveals two causes of haemorrhage in HELLP syndrome,” Br. J. Anaesth., vol. 74, no. 4, pp. 464–468, Apr. 1995, doi: 10.1093/BJA/74.4.464.
  • [5] C. M. Mihu and A. Seicean, “HELLP syndrome-A multisystemic disorder View project SONODIG View project,” Accessed: Jan. 26, 2022. [Online]. Available: https://www.researchgate.net/publication/5658642.
  • [6] R. D’Anna, “[The HELLP syndrome. Notes on its pathogenesis and treatment],” Minerva Ginecol., vol. 48, no. 4, pp. 147–154, Apr. 1996, Accessed: Jan. 26, 2022. [Online]. Available: https://europepmc.org/article/med/8767557.
  • [7] B. Haddad, J. R. Barton, J. C. Livingston, R. Chahine, and B. M. Sibai, “Risk factors for adverse maternal outcomes among women with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome,” Am. J. Obstet. Gynecol., vol. 183, no. 2, pp. 444–448, Aug. 2000, doi: 10.1067/MOB.2000.105915.
  • [8] S. mei Wan, Y. hong Yu, Y. ying Huang, and G. dong Su, “[Morbidity regularity of severe complications of hypertensive disorder complicating pregnancy in clinics].,” Zhonghua Fu Chan Ke Za Zhi, vol. 42, no. 8, pp. 510–514, Aug. 2007, Accessed: Jan. 26, 2022. [Online]. Available: https://europepmc.org/article/med/17983486.
  • [9] M. Armagan, O. Selen, O. Hülya, and U. Hasan Bozkaya, “Maternal outcome in HELLP syndrome requiring intensive care management in a Turkish hospital.”
  • [10] C. M. Isler, B. K. Rinehart, D. A. Terrone, R. W. Martin, E. F. Magann, and J. N. Martin, “Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome,” Am. J. Obstet. Gynecol., vol. 181, no. 4, pp. 924–928, Oct. 1999, doi: 10.1016/S0002-9378(99)70343-1.
  • [11] N. Prakash, T. McLeod, and F. Gao Smith, “The effects of remifentanil on haemodynamic stability during rigid bronchoscopy,” Anaesthesia, vol. 56, no. 6, pp. 576–580, Jan. 2001, doi: 10.1046/J.1365-2044.2001.01913-3.X.
  • [12] S. P. Ankichetty et al., “Regional anesthesia in patients with pregnancy induced hypertension,” J. Anaesthesiol. Clin. Pharmacol., vol. 29, no. 4, p. 435, Oct. 2013, doi: 10.4103/0970-9185.119108.
  • [13] P. J. Neligan and J. G. Laffey, “Clinical review: Special populations - critical illness and pregnancy,” Crit. Care, vol. 15, no. 4, pp. 1–10, Aug. 2011, doi: 10.1186/CC10256/TABLES/4.
  • [14] L. J. Santos Iglesias, J. L. Sánchez, J. A. Reboso Morales, C. Mesa del Castillo Payá, L. Fuster Puigdoménech, and F. González Miranda, “Anestesia general con remifentanilo en dos casos de cesárea urgente,” Rev. esp. anestesiol. reanim, pp. 244–247, 2001.
  • [15] A. Kapila et al., “Measured Context-sensitive Half-times of Remifentanil and Alfentanil,” Anesthesiology, vol. 83, no. 5, pp. 968–975, Nov. 1995, doi: 10.1097/00000542-199511000-00009.
  • [16] S. Aloizos et al., “HELLP syndrome: Understanding and management of a pregnancy-specific disease,” https://doi.org/10.3109/01443615.2013.775231, vol. 33, no. 4, pp. 331–337, May 2013, doi: 10.3109/01443615.2013.775231.

Anesthesia Management of Pregnant with HELLP Syndrome with Fetal Intrauterine Exitus

Year 2022, Volume: 39 Issue: 3, 913 - 915, 30.08.2022

Abstract

HELLP syndrome is a serious cause of mortality for pregnant women and requires careful anesthesia management. In this case, anesthesia management and intensive care clinic of a pregnant woman with intrauterine exitus due to preeclampsia and HELLP syndrome is presented.

References

  • [1] B. M. Sibai, “Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count,” Obstet. Gynecol., vol. 103, no. 5 I, pp. 981–991, 2004, doi: 10.1097/01.AOG.0000126245.35811.2a.
  • [2] H. Wulf, “[Anesthesia and intensive therapy of pregnant women with the HELLP syndrome],” Anaesthesist, vol. 39, no. 2, pp. 117–121, Feb. 1990, Accessed: Jan. 26, 2022. [Online]. Available: https://europepmc.org/article/med/2310003.
  • [3] D. Ben Letaifa et al., “[Maternal and perinatal morbidity and mortality associated with hellp syndrome] .,” Ann. Fr. Anesth. Reanim., vol. 19, no. 10, pp. 712–718, Dec. 2000, doi: 10.1016/S0750-7658(00)00313-0.
  • [4] R. K. S. Whitta, D. J. A. Cox, and S. V. Mallett, “Thrombelastography reveals two causes of haemorrhage in HELLP syndrome,” Br. J. Anaesth., vol. 74, no. 4, pp. 464–468, Apr. 1995, doi: 10.1093/BJA/74.4.464.
  • [5] C. M. Mihu and A. Seicean, “HELLP syndrome-A multisystemic disorder View project SONODIG View project,” Accessed: Jan. 26, 2022. [Online]. Available: https://www.researchgate.net/publication/5658642.
  • [6] R. D’Anna, “[The HELLP syndrome. Notes on its pathogenesis and treatment],” Minerva Ginecol., vol. 48, no. 4, pp. 147–154, Apr. 1996, Accessed: Jan. 26, 2022. [Online]. Available: https://europepmc.org/article/med/8767557.
  • [7] B. Haddad, J. R. Barton, J. C. Livingston, R. Chahine, and B. M. Sibai, “Risk factors for adverse maternal outcomes among women with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome,” Am. J. Obstet. Gynecol., vol. 183, no. 2, pp. 444–448, Aug. 2000, doi: 10.1067/MOB.2000.105915.
  • [8] S. mei Wan, Y. hong Yu, Y. ying Huang, and G. dong Su, “[Morbidity regularity of severe complications of hypertensive disorder complicating pregnancy in clinics].,” Zhonghua Fu Chan Ke Za Zhi, vol. 42, no. 8, pp. 510–514, Aug. 2007, Accessed: Jan. 26, 2022. [Online]. Available: https://europepmc.org/article/med/17983486.
  • [9] M. Armagan, O. Selen, O. Hülya, and U. Hasan Bozkaya, “Maternal outcome in HELLP syndrome requiring intensive care management in a Turkish hospital.”
  • [10] C. M. Isler, B. K. Rinehart, D. A. Terrone, R. W. Martin, E. F. Magann, and J. N. Martin, “Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome,” Am. J. Obstet. Gynecol., vol. 181, no. 4, pp. 924–928, Oct. 1999, doi: 10.1016/S0002-9378(99)70343-1.
  • [11] N. Prakash, T. McLeod, and F. Gao Smith, “The effects of remifentanil on haemodynamic stability during rigid bronchoscopy,” Anaesthesia, vol. 56, no. 6, pp. 576–580, Jan. 2001, doi: 10.1046/J.1365-2044.2001.01913-3.X.
  • [12] S. P. Ankichetty et al., “Regional anesthesia in patients with pregnancy induced hypertension,” J. Anaesthesiol. Clin. Pharmacol., vol. 29, no. 4, p. 435, Oct. 2013, doi: 10.4103/0970-9185.119108.
  • [13] P. J. Neligan and J. G. Laffey, “Clinical review: Special populations - critical illness and pregnancy,” Crit. Care, vol. 15, no. 4, pp. 1–10, Aug. 2011, doi: 10.1186/CC10256/TABLES/4.
  • [14] L. J. Santos Iglesias, J. L. Sánchez, J. A. Reboso Morales, C. Mesa del Castillo Payá, L. Fuster Puigdoménech, and F. González Miranda, “Anestesia general con remifentanilo en dos casos de cesárea urgente,” Rev. esp. anestesiol. reanim, pp. 244–247, 2001.
  • [15] A. Kapila et al., “Measured Context-sensitive Half-times of Remifentanil and Alfentanil,” Anesthesiology, vol. 83, no. 5, pp. 968–975, Nov. 1995, doi: 10.1097/00000542-199511000-00009.
  • [16] S. Aloizos et al., “HELLP syndrome: Understanding and management of a pregnancy-specific disease,” https://doi.org/10.3109/01443615.2013.775231, vol. 33, no. 4, pp. 331–337, May 2013, doi: 10.3109/01443615.2013.775231.
There are 16 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Case Report
Authors

İlke Tamdoğan 0000-0002-8757-1046

Esra Turunç 0000-0003-0159-7403

Early Pub Date August 30, 2022
Publication Date August 30, 2022
Submission Date June 2, 2022
Acceptance Date July 7, 2022
Published in Issue Year 2022 Volume: 39 Issue: 3

Cite

APA Tamdoğan, İ., & Turunç, E. (2022). Anesthesia Management of Pregnant with HELLP Syndrome with Fetal Intrauterine Exitus. Journal of Experimental and Clinical Medicine, 39(3), 913-915.
AMA Tamdoğan İ, Turunç E. Anesthesia Management of Pregnant with HELLP Syndrome with Fetal Intrauterine Exitus. J. Exp. Clin. Med. August 2022;39(3):913-915.
Chicago Tamdoğan, İlke, and Esra Turunç. “Anesthesia Management of Pregnant With HELLP Syndrome With Fetal Intrauterine Exitus”. Journal of Experimental and Clinical Medicine 39, no. 3 (August 2022): 913-15.
EndNote Tamdoğan İ, Turunç E (August 1, 2022) Anesthesia Management of Pregnant with HELLP Syndrome with Fetal Intrauterine Exitus. Journal of Experimental and Clinical Medicine 39 3 913–915.
IEEE İ. Tamdoğan and E. Turunç, “Anesthesia Management of Pregnant with HELLP Syndrome with Fetal Intrauterine Exitus”, J. Exp. Clin. Med., vol. 39, no. 3, pp. 913–915, 2022.
ISNAD Tamdoğan, İlke - Turunç, Esra. “Anesthesia Management of Pregnant With HELLP Syndrome With Fetal Intrauterine Exitus”. Journal of Experimental and Clinical Medicine 39/3 (August 2022), 913-915.
JAMA Tamdoğan İ, Turunç E. Anesthesia Management of Pregnant with HELLP Syndrome with Fetal Intrauterine Exitus. J. Exp. Clin. Med. 2022;39:913–915.
MLA Tamdoğan, İlke and Esra Turunç. “Anesthesia Management of Pregnant With HELLP Syndrome With Fetal Intrauterine Exitus”. Journal of Experimental and Clinical Medicine, vol. 39, no. 3, 2022, pp. 913-5.
Vancouver Tamdoğan İ, Turunç E. Anesthesia Management of Pregnant with HELLP Syndrome with Fetal Intrauterine Exitus. J. Exp. Clin. Med. 2022;39(3):913-5.